KRAS mutation: from undruggable to druggable in cancer
L Huang, Z Guo, F Wang, L Fu - Signal transduction and targeted …, 2021 - nature.com
Cancer is the leading cause of death worldwide, and its treatment and outcomes have been
dramatically revolutionised by targeted therapies. As the most frequently mutated oncogene …
dramatically revolutionised by targeted therapies. As the most frequently mutated oncogene …
The molecular biology of pancreatic adenocarcinoma: translational challenges and clinical perspectives
S Wang, Y Zheng, F Yang, L Zhu, XQ Zhu… - Signal transduction and …, 2021 - nature.com
Pancreatic cancer is an increasingly common cause of cancer mortality with a tight
correspondence between disease mortality and incidence. Furthermore, it is usually …
correspondence between disease mortality and incidence. Furthermore, it is usually …
Immune modulatory effects of oncogenic KRAS in cancer
Oncogenic KRAS mutations are the most frequent mutations in human cancer, but most
difficult to target. While sustained proliferation caused by oncogenic KRAS-downstream …
difficult to target. While sustained proliferation caused by oncogenic KRAS-downstream …
At the crossroads of immunotherapy for oncogene-addicted subsets of NSCLC
I Otano, AC Ucero, J Zugazagoitia… - Nature reviews Clinical …, 2023 - nature.com
Non-small-cell lung cancer (NSCLC) has become a paradigm of precision medicine, with
the discovery of numerous disease subtypes defined by specific oncogenic driver mutations …
the discovery of numerous disease subtypes defined by specific oncogenic driver mutations …
Protein synthesis control in cancer: selectivity and therapeutic targeting
Translational control of mRNAs is a point of convergence for many oncogenic signals
through which cancer cells tune protein expression in tumorigenesis. Cancer cells rely on …
through which cancer cells tune protein expression in tumorigenesis. Cancer cells rely on …
[HTML][HTML] Function and regulation of the PEA3 subfamily of ETS transcription factors in cancer
T Qi, Q Qu, G Li, J Wang, H Zhu, Z Yang… - American journal of …, 2020 - ncbi.nlm.nih.gov
The PEA3 subfamily is a subgroup of the E26 transformation-specific (ETS) family. Its
members, ETV1, ETV4, and ETV5, have been found to be overexpressed in multiple …
members, ETV1, ETV4, and ETV5, have been found to be overexpressed in multiple …
Comprehensive machine-learning survival framework develops a consensus model in large-scale multicenter cohorts for pancreatic cancer
L Wang, Z Liu, R Liang, W Wang, R Zhu, J Li, Z Xing… - Elife, 2022 - elifesciences.org
As the most aggressive tumor, the outcome of pancreatic cancer (PACA) has not improved
observably over the last decade. Anatomy-based TNM staging does not exactly identify …
observably over the last decade. Anatomy-based TNM staging does not exactly identify …
P53: a guardian of immunity becomes its saboteur through mutation
AD Agupitan, P Neeson, S Williams, J Howitt… - International journal of …, 2020 - mdpi.com
Awareness of the importance of immunity in controlling cancer development triggered
research into the impact of its key oncogenic drivers on the immune response, as well as …
research into the impact of its key oncogenic drivers on the immune response, as well as …
KRAS mutation: The booster of pancreatic ductal adenocarcinoma transformation and progression
Z Zhang, H Zhang, X Liao, H Tsai - Frontiers in Cell and …, 2023 - frontiersin.org
Pancreatic ductal adenocarcinoma (PDAC) is the most common type of pancreatic cancer. It
has a poor response to conventional therapy and has an extremely poor 5-year survival rate …
has a poor response to conventional therapy and has an extremely poor 5-year survival rate …
Mutant p53 activates hnRNPA2B1-AGAP1-mediated exosome formation to promote esophageal squamous cell carcinoma progression
R Feng, Y Yin, Y Wei, Y Li, L Li, R Zhu, X Yu, Y Liu… - Cancer Letters, 2023 - Elsevier
Abstract p53 mutations predispose cancer cell development, promote their survival and
metastasis, and lead to ineffective therapeutic responses and unfavorable prognosis. No …
metastasis, and lead to ineffective therapeutic responses and unfavorable prognosis. No …